EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

D4Z4 methylation and genetic modifiers influence severity in a facioscapulohumeral muscular dystrophy kindred

Russell J Butterfield iD, Diane M Dunn, Brett Duval, Sarah Moldt, Kristen Wong, Kevin M Flanigan, Mark F Leppert, Robert B Weiss

Brain · 17.11.2026

DOI: 10.1093/brain/awag124 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Brain, online erschienen am 17.11.2026. Verfasst von Russell J Butterfield und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, University of Utah, Salt Lake City, UT 84112, USA. Die Arbeit nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIH HHS, Ionis Pharmaceuticals, FSHD Society.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

One of the earliest systematic descriptions of facioscapulohumeral muscular dystrophy (FSHD) involved a six-generation kindred tracing back to a single ancestor born in 1775 in Lancashire, England, who later emigrated to Utah in the 1850s. First published in 1950, members of this kindred (K1462) have been followed clinically for decades, with DNA samples archived since the 1980s. Despite sharing the same 5-repeat unit (5RU) D4Z4 contraction on a permissive 4qA haplotype, affected individuals show marked variability in age at onset, clinical severity and disease progression, including within sibships. With long-term follow-up and a shared founder mutation, K1462 is a unique resource for identifying modifiers of disease expression in FSHD. We reintroduce K1462, with enrolment extending into the ninth generation, and perform genomic analysis using modern approaches. Inheritance of the 5RU founder allele was confirmed in 139 individuals, and nanopore Cas9-targeted sequencing determined CpG methylation across the contracted D4Z4 array at base-pair resolution. The 5RU allele showed complete penetrance; however, clinical severity and progression varied widely among affected individuals. Longitudinal analysis of blood-derived genomic DNA demonstrated high stability of D4Z4 CpG methylation within individuals, including samples collected up to 38 years apart, indicating long-term maintenance of the epigenetic state. In contrast, D4Z4 methylation levels differed substantially between individuals and showed a strong inverse correlation with clinical severity. Differences in D4Z4 methylation were observed both within and between families, with a modest but consistent parent-of-origin effect. Whole-genome sequencing analysis found no evidence that rare variants in known FSHD2 genes explained this variability. To assess the contribution of common genetic variation, we performed a pedigree-based genome-wide association analysis of D4Z4 methylation levels, identifying a single genome-wide significant locus on chromosome 15. Variants spanning the promoter and 5′ region of HDGFL3, which encodes a PWWP domain chromatin-interacting protein, were associated with increased D4Z4 methylation after accounting for parental transmission, supporting a role for common-variant modulation of methylation in FSHD. These results support a model in which D4Z4 methylation is established through transmission-associated epigenetic resetting, stably maintained within individuals, and quantitatively modified by inherited genetic variation. Together, these findings demonstrate that D4Z4 methylation is a stable, individual-level epigenetic feature that varies across a multigenerational pedigree in a manner that correlates with clinical severity, confirming D4Z4 methylation as a quantitative biomarker and genetically modifiable contributor to disease severity in FSHD.

Schlagwörter

Stichwörter der Autor:innen

HDGFL3CpG methylationD4Z4 macrosatelliteepigenetic regulationfacioscapulohumeral muscular dystrophygenetic modifier

Autor:innen und Institutionen

  • Department of Pediatrics, University of Utah, Salt Lake City, UT 84112, USA.
  • Department of Neurology, University of Utah, Salt Lake City, UT 84112, USA.
  • Department of Human Genetics, University of Utah, Salt Lake City, UT 84112, USA.
  • Center for Gene Therapy, The Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OH 43205, USA.
  • Department of Pediatrics, The Ohio State University, Columbus, OH 43205, USA.
  • Department of Neurology, The Ohio State University, Columbus, OH 43205, USA.

ORCID-Profile: Russell J Butterfield

Förderung

  • NIH HHS
  • Ionis Pharmaceuticals
  • FSHD Society
  • National Institutes of Health

Zitieren

APA

Butterfield, R. J., Dunn, D. M., Duval, B., Moldt, S., Wong, K., Flanigan, K. M., Leppert, M. F., & Weiss, R. B. (2026). D4Z4 methylation and genetic modifiers influence severity in a facioscapulohumeral muscular dystrophy kindred. Brain. https://doi.org/10.1093/brain/awag124

Vancouver

Butterfield RJ, Dunn DM, Duval B, Moldt S, Wong K, Flanigan KM, et al. D4Z4 methylation and genetic modifiers influence severity in a facioscapulohumeral muscular dystrophy kindred. Brain. 2026. doi:10.1093/brain/awag124

BibTeX
@article{Butterfield2026,
  author = {Butterfield, Russell J and Dunn, Diane M and Duval, Brett and Moldt, Sarah and Wong, Kristen and Flanigan, Kevin M and Leppert, Mark F and Weiss, Robert B},
  title = {D4Z4 methylation and genetic modifiers influence severity in a facioscapulohumeral muscular dystrophy kindred},
  journal = {Brain},
  year = {2026},
  doi = {10.1093/brain/awag124}
}
Kostenlos starten →